These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 35307742)

  • 1. Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study.
    Fangusaro JR; Onar-Thomas A; Poussaint TY; Wu S; Ligon AH; Lindeman NI; Banerjee A; Packer R; Kilburn LB; Pollack IF; Qaddoumi IA; Fisher PG; Dhall G; Baxter PA; Kreissman SG; Doyle LA; Smith MA; Fouladi M; Dunkel IJ
    Neuro Oncol; 2022 Aug; 24(8):1404. PubMed ID: 35307742
    [No Abstract]   [Full Text] [Related]  

  • 2. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.
    Banerjee A; Jakacki RI; Onar-Thomas A; Wu S; Nicolaides T; Young Poussaint T; Fangusaro J; Phillips J; Perry A; Turner D; Prados M; Packer RJ; Qaddoumi I; Gururangan S; Pollack IF; Goldman S; Doyle LA; Stewart CF; Boyett JM; Kun LE; Fouladi M
    Neuro Oncol; 2017 Aug; 19(8):1135-1144. PubMed ID: 28339824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study.
    Fangusaro J; Onar-Thomas A; Poussaint TY; Wu S; Ligon AH; Lindeman N; Campagne O; Banerjee A; Gururangan S; Kilburn LB; Goldman S; Qaddoumi I; Baxter P; Vezina G; Bregman C; Patay Z; Jones JY; Stewart CF; Fisher MJ; Doyle LA; Smith M; Dunkel IJ; Fouladi M
    Neuro Oncol; 2021 Oct; 23(10):1777-1788. PubMed ID: 33631016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
    Fangusaro J; Onar-Thomas A; Young Poussaint T; Wu S; Ligon AH; Lindeman N; Banerjee A; Packer RJ; Kilburn LB; Goldman S; Pollack IF; Qaddoumi I; Jakacki RI; Fisher PG; Dhall G; Baxter P; Kreissman SG; Stewart CF; Jones DTW; Pfister SM; Vezina G; Stern JS; Panigrahy A; Patay Z; Tamrazi B; Jones JY; Haque SS; Enterline DS; Cha S; Fisher MJ; Doyle LA; Smith M; Dunkel IJ; Fouladi M
    Lancet Oncol; 2019 Jul; 20(7):1011-1022. PubMed ID: 31151904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADC Histogram Analysis of Pediatric Low-Grade Glioma Treated with Selumetinib: A Report from the Pediatric Brain Tumor Consortium.
    Vajapeyam S; Brown D; Ziaei A; Wu S; Vezina G; Stern JS; Panigrahy A; Patay Z; Tamrazi B; Jones JY; Haque SS; Enterline DS; Cha S; Jones BV; Yeom KW; Onar-Thomas A; Dunkel IJ; Fouladi M; Fangusaro JR; Poussaint TY
    AJNR Am J Neuroradiol; 2022 Mar; 43(3):455-461. PubMed ID: 35210278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating Focal Areas of Signal Intensity (FASI) in Children with Neurofibromatosis Type-1 (NF1) Treated with Selumetinib on Pediatric Brain Tumor Consortium (PBTC)-029B.
    Pillay-Smiley N; Leach J; Lane A; Hummel T; Fangusaro J; de Blank P
    Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium.
    Zukotynski KA; Fahey FH; Kocak M; Alavi A; Wong TZ; Treves ST; Shulkin BL; Haas-Kogan DA; Geyer JR; Vajapeyam S; Boyett JM; Kun LE; Poussaint TY
    J Nucl Med; 2011 Feb; 52(2):188-95. PubMed ID: 21233173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study.
    Baxter PA; Su JM; Onar-Thomas A; Billups CA; Li XN; Poussaint TY; Smith ER; Thompson P; Adesina A; Ansell P; Giranda V; Paulino A; Kilburn L; Quaddoumi I; Broniscer A; Blaney SM; Dunkel IJ; Fouladi M
    Neuro Oncol; 2020 Jun; 22(6):875-885. PubMed ID: 32009149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation.
    Imyanitov EN; Levchenko EV; Kuligina ES; Orlov SV
    Expert Opin Pharmacother; 2020 Nov; 21(16):1943-1953. PubMed ID: 32880495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.
    Wetmore C; Daryani VM; Billups CA; Boyett JM; Leary S; Tanos R; Goldsmith KC; Stewart CF; Blaney SM; Gajjar A
    Cancer Med; 2016 Jul; 5(7):1416-24. PubMed ID: 27109549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018.
    Warren KE; Goldman S; Pollack IF; Fangusaro J; Schaiquevich P; Stewart CF; Wallace D; Blaney SM; Packer R; Macdonald T; Jakacki R; Boyett JM; Kun LE
    J Clin Oncol; 2011 Jan; 29(3):324-9. PubMed ID: 21149652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.
    Deming DA; Cavalcante LL; Lubner SJ; Mulkerin DL; LoConte NK; Eickhoff JC; Kolesar JM; Fioravanti S; Greten TF; Compton K; Doyle AG; Wilding G; Duffy A; Liu G
    Invest New Drugs; 2016 Apr; 34(2):168-75. PubMed ID: 26666244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low-Grade Gliomas.
    Patel YT; Daryani VM; Patel P; Zhou D; Fangusaro J; Carlile DJ; Martin PD; Aarons L; Stewart CF
    CPT Pharmacometrics Syst Pharmacol; 2017 May; 6(5):305-314. PubMed ID: 28326681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC-042).
    Van Mater D; Gururangan S; Becher O; Campagne O; Leary S; Phillips JJ; Huang J; Lin T; Poussaint TY; Goldman S; Baxter P; Dhall G; Robinson G; DeWire-Schottmiller M; Hwang EI; Stewart CF; Onar-Thomas A; Dunkel IJ; Fouladi M
    Pediatr Blood Cancer; 2021 Apr; 68(4):e28879. PubMed ID: 33405376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012.
    MacDonald TJ; Stewart CF; Kocak M; Goldman S; Ellenbogen RG; Phillips P; Lafond D; Poussaint TY; Kieran MW; Boyett JM; Kun LE
    J Clin Oncol; 2008 Feb; 26(6):919-24. PubMed ID: 18281665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study.
    Salloum R; Hummel TR; Kumar SS; Dorris K; Li S; Lin T; Daryani VM; Stewart CF; Miles L; Poussaint TY; Stevenson C; Goldman S; Dhall G; Packer R; Fisher P; Pollack IF; Fouladi M; Boyett J; Drissi R
    J Neurooncol; 2016 Sep; 129(3):443-451. PubMed ID: 27350411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).
    Fangusaro J; Gururangan S; Poussaint TY; McLendon RE; Onar-Thomas A; Warren KE; Wu S; Packer RJ; Banerjee A; Gilbertson RJ; Jakacki R; Gajjar A; Goldman S; Pollack IF; Friedman HS; Boyett JM; Kun LE; Fouladi M
    Cancer; 2013 Dec; 119(23):4180-7. PubMed ID: 24104527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the mitogen‑activated protein kinase kinase and protein kinase A pathways overcomes acquired resistance to Selumetinib in low‑grade glioma cells.
    Melotti L; Meco D; Battaglia A; Buzzonetti A; Martini M; Ruggiero A; Scambia G; Riccardi R
    Oncol Rep; 2021 Feb; 45(2):752-763. PubMed ID: 33416182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.
    Holkova B; Zingone A; Kmieciak M; Bose P; Badros AZ; Voorhees PM; Baz R; Korde N; Lin HY; Chen JQ; Herrmann M; Xi L; Raffeld M; Zhao X; Wan W; Tombes MB; Shrader E; Weir-Wiggins C; Sankala H; Hogan KT; Doyle A; Annunziata CM; Wellons M; Roberts JD; Sullivan D; Landgren O; Grant S
    Clin Cancer Res; 2016 Mar; 22(5):1067-75. PubMed ID: 26446942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
    Gururangan S; Petros WP; Poussaint TY; Hancock ML; Phillips PC; Friedman HS; Bomgaars L; Blaney SM; Kun LE; Boyett JM
    Clin Cancer Res; 2006 Mar; 12(5):1540-6. PubMed ID: 16533779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.